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LEAKS DURING POST-OPERATIVE PULMONARY SURGERY USING THE 
MEDICARE POPULATION
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1Quintiles, Rockville, MD, USA; 2Quintiles Global Consulting, Hawthorne, NY, USA; 
3Quintiles Consulting, Durham, NC, USA; 4Quintiles, Falls Church, VA, USA; 5Triage 
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OBJECTIVES: Estimate the clinical and economic impact to U.S. hospitals of air leaks 
during post-operative pulmonary surgery using the Medicare Provider Analysis and 
Review (MEDPAR) data set. METHODS: The 2008 The Medicare Provider Analysis 
and Review (MEDPAR) data set contains records for 100% of Medicare beneﬁ ciaries 
who use hospital inpatient services. For all stays with pulmonary surgery, length of 
stay (LOS), total charges, and in-hospital mortality rates were compared between those 
stays including an air leak vs. those stays without an air leak. Unadjusted results were 
calculated using descriptive statistics (mean, median, frequencies, etc.) Adjusted results 
were calculated using multivariate regression analysis while controlling for age and 
gender. RESULTS: There were a total of 41,348 hospital inpatient stays with pulmo-
nary surgery in the 2008 MEDPAR data set, of these 8,774 (21.2%) included air leak 
and 32,574 (78.8%) of which did not. In the MEDPAR data set patients with pulmo-
nary surgery stays including air leak had a similar age distribution to patients without 
air leak, had a longer LOS on average (10.7 days vs. 7.2 days; P < .0001), had more 
total charges ($78,830 vs. $63,528; P < .0001) and were nearly equally likely to die 
during their stay (14.8% vs. 13.94%; p = 0.057). After adjusting for differences in 
age and gender between the two groups, the incremental LOS and total charges due 
to the presence of air leak is 3.4 days and $14,532 respectively. The total additional 
economic impact of having an air leak after pulmonary surgery, estimated by applying 
patient level adjusted charges to the incidence of air leak, is $127.5 million. CONCLU-
SIONS: The clinical and economic impact to U.S. hospitals of air leaks during or 
following major pulmonary surgery is signiﬁ cant. The reduction of these air leaks 
could save considerable hospital resources, payer dollars and patient lives.
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OUTCOMES ASSOCIATED WITH IATROGENIC PNEUMOTHORAX
Stemkowski S1, Braxton JC2
1Lovelace Respiratory Research Institute, Kannapolis, NC, USA; 2Davidson College, Davidson, 
NC, USA
OBJECTIVES: Iatrogenic pneumothorax occurs when air or gas becomes present in 
the pleural cavity following medical treatment. Besides subjecting the patient to 
unnecessary health risks, iatrogenic pneumothorax leads to an increased amount of 
health care resources including observed through patient cost, length of stay, and 
inpatient mortality. This research aims to quantify the incremental effects of iatrogenic 
pneumothorax on these three outcomes. METHODS: Discharge records from Pre-
mier’s Perspective database of US inpatients who underwent inpatient pulmonary 
surgery and were discharged in 2007 were examined. The deﬁ nition of iatrogenic 
pneumothorax consistent with ICD-9-CM code 512.1 was used to classify patients. 
Chi-square tests were used to detect differences between iatrogenic pneumothorax 
patients and non-iatrogenic pneumothorax patients for three outcomes. Multivariable 
regression models were used to obtain more precise estimates of the incremental effects 
of iatrogenic pneumothorax on outcomes while controlling for comorbidities, demo-
graphic variables and the patient’s primary treatment. RESULTS: A total of 112,827 
patients were analyzed (8,482 with iatrogenic pneumothorax). Chi-square tests dem-
onstrated that patients with iatrogenic pneumothorax were older (P < 0.0001), had 
lower hospital costs (P < 0.0001), a shorter length of stay (P < 0.0001), and lower 
mortality rate (P < 0.0001). Log linear modeling demonstrated iatrogenic pneumotho-
rax increases patient costs by 10.49% (95%CI: 8.76%–12.23%). Negative binomial 
models showed iatrogenic pneumothorax increases patients length of stay by 8.01% 
(95% CI: 6.21%–9.82%), while no difference was found with respect to mortality. 
CONCLUSIONS: The incremental effects of iatrogenic pneumothorax are shown to 
signiﬁ cantly increase patient costs and length of stay but not inpatient mortality.
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BURDEN OF BRONCHIAL ASTHMA AND CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE IN RUSSIA
Omelyanovsky VV1, Avksentieva MV1, Derkach EV1, Tsfasman FM2, Sveshnikova ND1
1Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Moscow, 
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OBJECTIVES: to assess social and economic burden of a Bronchial asthma and 
Chronic Obstructive Pulmonary Disease in Russian Federation. METHODS: “Cost 
of illness” analysis was performed. Available data on epidemiology of bronchial 
asthma and chronic obstructive pulmonary disease in the Russian Federation has been 
analyzed. Experts were questioned to describe the common practice of treating patients 
with bronchial asthma and chronic obstructive pulmonary disease. Direct costs, indi-
rect costs and intangible costs were calculated. RESULTS: According to the state 
registration data, in 2007 the number of patients with bronchial asthma was 1.3 
million and with chronic obstructive pulmonary disease— 2.4 million. The burden of 
bronchial asthma incorporates direct costs (c220.9 million), indirect costs (c67.4 
million) and intangible costs (c69.6 million). The burden of chronic obstructive pul-
monary disease is c210.6 million, c212 million, c207 million for direct costs, indirect 
costs and intangible costs respectively. Cost of BA and COPD is c987.8 million. 
CONCLUSIONS: According to the results of the analysis Bronchial asthma and 
Chronic Obstructive Pulmonary Disease proved to be an important medical and social 
problem in Russian Federation.
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COST OF COPD IN POLAND
Jahnz-Rozyk KM, Targowski T, From S, Faluta T, Borowiec L
Military Institute of Medicine, Warsaw, Poland
OBJECTIVES: About two million people suffer from COPD in Poland. The aim of 
this study was to examine direct, mean costs of COPD in Poland under usual clinical 
practice form societal perspective. METHODS: It was an observational retrospective 
and prospective bottom-up-cost-of- illness study, based on a retrospective sample of 
patients presenting with COPD. Total medical resources consumption of a sample of 
COPD patients were collected in 2008 year trough physician—lung specialists. Direct 
costs of COPD were evaluated based on data from different populations of ﬁ ve clinical 
hospitals and eight ambulatory cares. Medical resource consumptions were catego-
rized by investigators as usual COPD follow up and number and severity of exacerba-
tions.Resources utilization and cost data are summarised as mean values per patient 
per year; 95% conﬁ dence intervals were derived using percentile bootstrapping. 
RESULTS: In patients studied, number of free –of- exacerbation days was 331, 1, 
mean number of outpatient exacerbation was 1.27, mean number of exacerbations 
requiring hospital was 0.24. Average total medical resource consumption of a COPD 
patient per year was c1006.1. Among this cost c605 was directly related to treatment 
of stable COPD (costs of drugs, additional exams, costs of medical visits, inﬂ uenza 
vaccination and home oxygen therapy), c105.3 to outpatient exacerbation, and c295.8 
to exacerbation treated in hospital. CONCLUSIONS: The burden of COPD itself 
appeared to be considerable magnitude from societal perspective in Poland. Overall, 
the main cost drivers were inpatient care and prescription medication.
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OBJECTIVES: We compared two alternative methods (recycled prediction and Oax-
aca-decomposition) to estimate medical costs attributable to obesity in US adults with 
asthma. METHODS: This study used the 2003–2007 Medical Expenditure Panel 
Survey to select asthma patients (18–64 years old), excluding patients with pregnancy, 
malignancy, kidney dialysis, immunodeﬁ ciency, or low body mass index (BMI < 18.5 
kg/m2). Obesity was deﬁ ned as BMI >= 30 kg/m2. Medication costs were estimated 
using a generalized linear model with a log-link function and gamma distribution. For 
the recycled predictions method, predicted treatment costs for obese patients were 
calculated assuming that obese patients were normal-weight, holding the distribution 
of covariates obtained from the entire asthma patient sample. With Oaxaca-decom-
position, average treatment costs for each group (obese vs. normal weight) were 
estimated. The differences in average costs between the two groups were then esti-
mated for two components: a) costs due to patient characteristics (endowments), and 
b) costs due to obese/normal-weight parameters (coefﬁ cient), considered as costs 
attributable to obesity. To compare the two methods, the difference in costs between 
obese and normal-weight patients was simulated, after matching for patient demo-
graphic and clinical characteristics,. All costs were converted to 2009 US dollars using 
price indices. RESULTS: The prevalence of obesity and normal-weight among 7340 
asthmatic patients was 32.5% vs. 35.1%, respectively. In the recycled prediction 
method, costs attributable to obesity were US$1798 (95%CI: US$1717–$1878). In 
the Oaxaca-decomposition, the difference in medical costs between two groups con-
sisted of US$1357 (95%CI: US$1252–$1462) due to endowments and US$1285 (95% 
CI: US$1229–$1341) due to coefﬁ cient components (i.e. costs attributable to obesity). 
The difference in costs from the simulation was US$1124 (US$1045–US$1203). CON-
CLUSIONS: Costs attributable to obesity obtained using Oaxaca-decomposition were 
similar to those of the simulation method, but the costs obtained using the recycled 
prediction method were higher than those of Oaxaca-decomposition and 
simulation.
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LONG-TERM EFFECTIVENESS AND COST-EFFECTIVENESS OF SMOKING 
CESSATION INTERVENTIONS IN PATIENTS WITH COPD
Hoogendoorn M1, Feenstra T2, Hoogenveen RT3, Rutten-van Mölken MP1
1Erasmus University, Rotterdam, The Netherlands; 2RIVM /UMCG, Bilthoven, The 
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OBJECTIVES: We aimed to estimate the long-term (cost-)effectiveness of smoking 
cessation interventions for patients with chronic obstructive pulmonary disease 
(COPD). METHODS: A systematic review was performed for randomized controlled 
trials on smoking cessation interventions in COPD patients reporting the 12-month 
biochemical validated abstinence rates. The different interventions were grouped into 
four categories: usual care, minimal counseling, intensive counseling and intensive 
counseling plus pharmacotherapy. For each category the average 12-months continu-
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ous abstinence rate and intervention costs were estimated. a dynamic population 
model for COPD was used to project the long-term (cost-)effectiveness of one year 
implementation of minimal counseling, intensive counseling and intensive counseling 
plus pharmacotherapy for 50% of the smoking COPD patients compared to usual 
care. Time horizon was 25 years. Uncertainty and one-way sensitivity analyses were 
performed for variations in (the calculation of) the abstinence rates, the type of projec-
tion, intervention costs and discount rates. RESULTS: Nine studies were selected. The 
average 12 months continuous abstinence rates were estimated to be 1.4% for usual 
care, 2.6% for minimal counseling, 6.0% for intensive counseling and 12.3% for 
pharmacotherapy. Compared to usual care, the costs per QALY gained for minimal 
counseling, intensive counseling and intensive counseling plus pharmacotherapy were 
c16,900, c8,200 and c2,400, respectively. Results were most sensitive to variations in 
abstinence rates and discount rates. CONCLUSIONS: Compared to usual care inten-
sive counseling and pharmacotherapy resulted in low costs per QALY gained with 
ratios comparable to results presented for smoking cessation in the general population. 
Compared to intensive counseling alone, intensive counseling plus pharmacotherapy 
was cost saving and dominated the other interventions.
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A COST-UTILITY ANALYSIS FOR TIOTROPIUM BROMIDE IN THE LONG 
TERM TREATMENT OF SPECIFIC SUBGROUPS OF ITALIAN COPD 
PATIENTS
Zaniolo O, Iannazzo S, Carsi M
Adres srl, Torino, Italy
OBJECTIVES: The UPLIFT trial demonstrated in 5,993 patients with moderate to 
very-severe chronic obstructive pulmonary disease (COPD) that 4 years of tiotropium 
bromide were associated with improvements in lung function, quality of life, and 
exacerbations compared with placebo. The aim of this study is the economic assess-
ment of tiotropium when included in COPD routine care (RC) for speciﬁ c groups of 
Italian COPD patients. METHODS: A probabilistic patient-level simulation Markov 
model was developed over a lifetime horizon, with one-year cycles and a 3.5% annual 
discount rate. Patients were characterized by gender, age, height, smoking status and 
FEV1. FEV1 time trend was modelled based on the decline recorded in UPLIFT. The 
mortality of the general Italian population adjusted by smoking status and FEV1 was 
adopted. Health utilities derived from published Italian studies, while their variation 
from the UPLIFT. Exacerbation rates derived from an Italian observational prospec-
tive study and were adjusted for the relative risk (RR) reported in UPLIFT. Direct 
sanitary costs were considered. Health care resource consumption for RC, exacerba-
tions and SAEs derived from Italian observational studies and were valued according 
to current price and tariffs. Cost-effectiveness was assessed for the overall cohort and 
for subgroups of patients by age, sex, GOLD stage and smoking attitude. RESULTS: 
In the whole cohort, patients treated with tiotropium gained an average (95%CI) 0.50 
(−1.63– −6.27) LYs and 0.42 (−0.25– −3.05) QALYs with respect to RC. The incre-
mental lifetime cost was c3,357 (−c10,669– −c29,820). The incremental cost-effec-
tiveness ratio (ICER) was c7,916 /QALY. In the subgroups analysis the ICER ranged 
from a minimum of c6,627/QALY (females, GOLD III) to a maximum of c13,187/
QALY (age <65 y, GOLD IV). CONCLUSIONS: The inclusion of tiotropium in RC 
for moderate to very severe COPD patients represents good value for money in Italy. 
The analysis across subgroups demonstrated a good stability of the model.
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COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF 
MOMETASONE FUROATE AS MAINTENANCE TREATMENT IN 
PATIENTS WITH MILD TO MODERATE ASTHMA FROM THE PUBLIC 
PAYER PERSPECTIVE IN BRAZIL
Fernandes RA, Takemoto ML, Cukier FN, Guerra FC, Passos RB
ANOVA—Knowledge Translation, Rio de Janeiro, RJ, Brazil
OBJECTIVES: In the Brazilian public health care system, mometasone furoate (MF 
DPI) is not available and budesonide/formoterol (BUD/FF DPI) association is respon-
sible for 86.9% of pharmacy claims for asthma. This study aimed to conduct cost-
effectiveness and budget impact analysis (BIA) of MF versus BUD/FF for adult patients 
with mild to moderate asthma from the public payer perspective. METHODS: A 
decision tree was developed to compare MF and BUD/FF based on indirect comparison 
once head-to-head studies were not available. The ﬁ nal FEV1 values were converted 
into probabilities of hospitalization in the ﬁ rst two years in accordance with observa-
tional evidence of association between FEV1 and exacerbation requiring hospitaliza-
tion. Only direct medical costs were considered and unit costs were obtained from 
Brazilian ofﬁ cial lists. BIA assumed pharmacy claims data from the Ambulatory 
Information System as current scenario (Beclomethasone: 3.1%; BUD: 9.9%; BUD/
FF: 86.9%) and a 20% initial market share for MF in substitution to equivalent doses 
of BUD/FF. RESULTS: Indirect comparison indicated 79 hospitalizations per 1000 
patients for MF and 82 for BUD/FF during the ﬁ rst 2 years of treatment. Total cost 
of treatment was 832BRL and 655BRL per patient for MF200 mcg twice a day (bid) 
and MF400 mcg once a day and 840BRL for BUD/FF 400/12 mcg bid. These ﬁ ndings 
indicated MF as cost-saving in the proposed scenario with ICER of −2.608BRL and 
−61.959BRL per avoided hospitalization for MF200 mcg and MF400 mcg, respec-
tively. The estimated budgetary impact for the ﬁ rst year showed a saving of 
259,346,480BRL for MF 400 mcg and 10,919,299BRL for MF 200 mcg. CONCLU-
SIONS: MF is a clinically effective option to treat mild to moderate asthma and 
indirect comparison showed its clinical and economic beneﬁ t when compared to the 
most used anti-asthma medication in the Brazilian public setting. Further research to 
directly compare both medications and to measure ﬁ nalistic outcomes alongside clini-
cal trials is needed.
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COUNTRY ADAPTATION OF A HEALTH ECONOMIC MODEL: THE 
CASE FOR ROFLUMILAST IN THE NETHERLANDS
Vemer P, Goossens LM, Rutten-Van Mölken MP
Erasmus University, Rotterdam, The Netherlands
BACKGROUND: The phosphodiesterase-4 enzyme (PDE4) inhibitor roﬂ umilast is a 
new treatment that targets the underlying inﬂ ammation associated with COPD. When 
approved, roﬂ umilast will be registered as an add-on to bronchodilator treatment in 
adult patients with severe COPD, with a history of frequent exacerbations. a health 
economic (HE) micro-simulation Markov model was used to support its submission 
in the United Kingdom (UK). Pharmaceutical companies can save signiﬁ cantly on the 
process of HE evidence development, if models can be adapted for use in more than 
one country. OBJECTIVES: To transfer an existing UK HE model to the The Neth-
erlands in order to calculate the cost-effectiveness (CE) of roﬂ umilast in patients with 
severe COPD from a societal perspective. METHODS: The model structure was 
adapted to include production loss using the friction cost method, and to separate 
heterogeneity from parameter uncertainty. All input parameters on health care use, 
costs, utilities, and COPD epidemiology were obtained from Dutch sources, except 
for the case-fatality rate of an exacerbation-related hospitalization. a direct compari-
son was made between a combination of a long-acting β2 agonist (LABA) plus 
roﬂ umilast (ROFLU) and LABA alone. a second, indirect comparison was between 
LABA + ROFLU and LABA plus an inhaled corticosteroid (ICS). One-way and proba-
bilistic sensitivity analyses were performed. RESULTS: From a societal perspective, 
the incremental CE ratio (ICER) for LABA + ROFLU compared with LABA alone, 
was c7900. The ICER of LABA + ROFLU versus LABA + ICS was c10,000. The 
probability that LABA + ROFLU was cost-effective when compared with LABA alone 
at a threshold of c20,000 versus LABA was 97%. Compared with LABA + ICS this 
probability was 68.3%. CONCLUSIONS: The original UK model was suitable for 
adaptation to the Dutch setting. The ICERs of roﬂ umilast were below commonly 
referred threshold values of a QALY.
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OBJECTIVES: To estimate the incremental cost-effectiveness of SFC verus montelu-
kast in adult patients with persistent asthma. METHODS: A decision-analytic model 
was developed from a randomized, double-blind, double-dummy, 12-week clinical 
trial were analyzed. Efﬁ cacy end points included, symptom-free days (SFDs) during 
the 12-week period. The study assumed the Mexican health care perspective with costs 
in 2010 US dollars, and hence only direct costs were included in the analysis. Direct 
costs included those related to study drugs, emergency room department visits, 
unscheduled physician visits, and rescue medication. The incremental cost-effective-
ness ratio (ICER), which is the mean difference in average costs divided by the mean 
difference in average effectiveness, was calculated for the effectiveness outcomes 
(SFDs). Issue of uncertainty was addressed by means of a probabilistic Monte Carlo 
simulation, which attributed stochastic distributions to model inputs. RESULTS: 
Treatment with FSC resulted in a signiﬁ cantly greater improvement in the mean 
percentage of symptom-free days compared with MON 48.9 and 21.7 respectively (p 
0.001). In the base case, patients initiated on SFC displayed a 45% reduction in overall 
cost as compared with patients initiated on MON US S186 versus $US258, respec-
tively, respectively). SFC dominated the use of MON because of previously demon-
strated lower incidence of Asthma exacerbations and rescue free days. Sensitivity 
analyses determined that univariate changes in all model variables, including medica-
tion cost, and cost of treating exacerbation, did not impact overall results. a Monte 
Carlo simulation analysis found that use of SFC remains the best overall treatment 
strategy when taking into consideration the potential variance in all model assump-
tions. Compared with MON, SFC is estimated to be both more effective and more 
economically favourable, with a probability of almost 92%. CONCLUSIONS: The 
decision model indicated that use of SFC as treatment in patients with asthma should 
result in lower overall treatment costs relative to the cost of MON.
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COMBINATION VERSUS LEUKOTRIENE MONTELUKAST FOR THE 
CONTROL OF PERSISTENT ASTHMA IN CHILDREN
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OBJECTIVES: To assess the incremental cost-effectiveness of SFC compared with 
MON for the control of persistent asthma in children. METHODS: We conducted an 
economic evaluation on a 12-week prospective randomized open-label parallel-group 
